Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last461 to 480 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| CSL112 vs Placebo: Number of Participants With First Occurrence of MI | 312 of 9,112 342 of 9,107 | -0.3 points -0.9 to 0.2 | 18,219 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: Number of Participants With Occurrence of All-cause Death | 341 of 9,112 345 of 9,107 | -0.0 points -0.6 to 0.5 | 18,219 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) | 439 of 9,112 472 of 9,107 | -0.4 points -1.0 to 0.3 | 18,219 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: Number of Participants With First Occurrence of CV Death, MI, or Stroke | 622 of 9,112 683 of 9,107 | -0.7 points -1.4 to 0.1 | 18,219 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: Number of Participants With First Occurrence of CV Death, MI, or Stroke | 885 of 9,112 944 of 9,107 | -0.7 points -1.5 to 0.2 | 18,219 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: Number of Participants With First Occurrence of Stroke | 57 of 9,112 49 of 9,107 | 0.1 points -0.1 to 0.3 | 18,219 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: deaths from any cause | 348 of 9,112 355 of 9,107 | -0.1 points -0.6 to 0.5 | 18,219 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: Number of Participants With Occurrence of CV Death | 107 of 9,112 128 of 9,107 | -0.2 points -0.6 to 0.1 | 18,219 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| Apixaban vs Warfarin: Number of Participants With Events of All-Cause Death During the Intended Treatment Period | 603 of 9,120 669 of 9,081 | -0.8 points -1.5 to -0.0 | 18,201 | NCT00412984 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| Ezetimide/Simvastatin vs Simvastatin: serious adverse events | 3,640 of 9,067 3,649 of 9,077 | -0.1 points -1.5 to 1.4 | 18,144 | NCT00202878 IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103) |
| Apixaban vs Warfarin: Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period | 613 of 9,088 877 of 9,052 | -2.9 points -3.7 to -2.1 | 18,140 | NCT00412984 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| Apixaban vs Warfarin: Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period | 327 of 9,088 462 of 9,052 | -1.5 points -2.1 to -0.9 | 18,140 | NCT00412984 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| Apixaban vs Warfarin: Number of Participants With All Bleeding Events During Treatment Period | 2,356 of 9,088 3,060 of 9,052 | -7.9 points -9.2 to -6.6 | 18,140 | NCT00412984 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| Apixaban vs Warfarin: Number of Participants With Net-Clinical Benefit During Treatment Period | 459 of 9,088 608 of 9,052 | -1.7 points -2.4 to -1.0 | 18,140 | NCT00412984 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| Warfarin vs Apixaban: serious adverse events | 3,182 of 9,088 3,302 of 9,052 | -1.5 points -2.9 to -0.1 | 18,140 | NCT00412984 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation |
| CSL112 vs Placebo: Number of Participants With Treatment-related Adverse Events | 350 of 9,010 304 of 9,027 | 0.5 points -0.0 to 1.1 | 18,037 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: Number of Participants With Serious Adverse Events (SAEs) | 1,514 of 9,010 1,557 of 9,027 | -0.4 points -1.5 to 0.7 | 18,037 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: Number of Participants With Adverse Events | 3,938 of 9,010 3,927 of 9,027 | 0.2 points -1.2 to 1.7 | 18,037 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| CSL112 vs Placebo: serious adverse events | 1,514 of 9,010 1,557 of 9,027 | -0.4 points -1.5 to 0.7 | 18,037 | NCT03473223 Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome |
| ROSUVASTATIN 20 MG vs PLACEBO: serious adverse events | 1,205 of 8,869 1,216 of 8,864 | -0.1 points -1.1 to 0.9 | 17,733 | NCT00239681 JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=24
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03473223-14903782",
"title": "CSL112 vs Placebo: Number of Participants With First Occurrence of MI",
"summary": "312 of 9112 against 342 of 9107; risk difference -0.3 points, 95% interval -0.9 to 0.2; NCT03473223, Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome",
"record": "/library/comparisons/NCT03473223-14903782",
"nct_id": "NCT03473223",
"kind": "outcome",
"participants": 18219,
"risk_difference": {
"value": -0.0033129683550545755,
"lower": -0.008733697779427178,
"upper": 0.0020972635497298825
},
"group_1": "312 of 9,112",
"group_2": "342 of 9,107",
"difference": "-0.3 points",
"interval": "-0.9 to 0.2",
"trial_title": "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome"
},
{
"id": "NCT03473223-17308645",
"title": "CSL112 vs Placebo: Number of Participants With Occurrence of All-cause Death",
"summary": "341 of 9112 against 345 of 9107; risk difference -0.0 points, 95% interval -0.6 to 0.5; NCT03473223, Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome",
"record": "/library/comparisons/NCT03473223-17308645",
"nct_id": "NCT03473223",
"kind": "outcome",
"participants": 18219,
"risk_difference": {
"value": -0.000459768956970745,
"lower": -0.0060012881271683345,
"upper": 0.005080187023452176
},
"group_1": "341 of 9,112",
"group_2": "345 of 9,107",
"difference": "-0.0 points",
"interval": "-0.6 to 0.5",
"trial_title": "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=25",
"request_id": "zMb-ZWk6PJgwVbwr"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant